U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07352969) titled 'A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients' on Jan. 13.
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
Study Start Date: Feb. 06
Study Type: INTERVENTIONAL
Condition:
Hypertension
Intervention:
DRUG: IBI3016
Solution of Injection
OTHER: Placebo
0.9% sodium chloride saline solution
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Published by HT Digital Content Services with...